Exscientia · pitchdeck
Exscientia | Investor Presentation Deck | 76 slides
76 pages · 4 arc beats · 1 loops
Exscientia | Investor Presentation Deck | 76 slides
Exscientia · 2023-11 arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
15101520253035404550556065707576
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 6 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits — 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Traction 3 slides 100% 3/3 slides 100% 3/3 slides · 25 hits — 0/3 slides
33.3% 1/3 slides 33.3% 1/3 slides 100% 3/3 slides — 0/3 slides
Business Model 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides — 0/1 slides
Slide inventory
76 every slide · same image gating as the playbook
04
The slide uses a 3x2 grid layout to present key performance indicators.show_traction
Open slide detailBeat · Traction
06
The slide uses a simple additive framework to show the synergy between two companies.show_traction
Open slide detailBeat · Traction
08
The slide uses a hub-and-spoke style circular process diagram centered on a human silhouette.present_solution
09
The slide uses a table to highlight the unique value proposition of four specific clinical programs.compare_peers
Open slide detailLoop · Cost Of Inaction
10
The chart uses a horizontal bar format to represent the development stage of each program.plan_implementation
11
The diagram is a concentric circle model representing the layers of value in collaborations.present_framework
Open slide detailBeat · Business Model
12
The slide uses a stepped arrow diagram to show progression from known targets to challenging novel targets.plan_implementation
13
Includes footnote regarding fixed term bank deposits and currency basis.show_traction
15
The slide uses a complex flow diagram combining a linear process with two internal feedback loops (Active Learning).present_solution
16
The slide uses a circular process flow to represent a proprietary R&D pipeline.present_solution
17
The slide uses a process flow diagram to illustrate a clinical success story.show_traction
18
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.show_traction
19
The slide uses a horizontal process-like layout to showcase four distinct technical pillars.present_solution
20
The slide uses a circular flow diagram to represent the integration of AI and experimental biology.present_solution
21
The diagram illustrates a flywheel-like process of data integration leading to novel targets.present_solution
22
The slide uses a hierarchical clustering heatmap (dendrograms on top and left) to visualize drug sensitivity across 80 small molecules.frame_problem
23
The slide illustrates a computational drug discovery workflow using MPO (Multiparameter Optimisation).present_solution
24
The diagram uses a hub-and-spoke model to show data integration, followed by a funnel for molecule generation and a circular feedback loop for active learning.present_solution
25
The slide features a 3D molecular model and a UI overlay showing various drug discovery metrics like potency, selectivity, and toxicity.present_solution
26
The scatter plot highlights a specific cluster of 'active learning' selections that deviate from the standard Pareto frontier.present_solution
27
The slide uses a small multiples approach to show dose-response curves across multiple patient samples, followed by a summary plot comparing the two groups overanalyze_data
30
The slide uses a molecular visualization as a background element to emphasize the drug's mechanism of action.show_traction
31
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).plan_implementation
32
The slide uses a human anatomy diagram to map specific cancer types to their respective organs, totaling approximately 75,000 patients annually.size_opportunity
33
Includes a biological pathway diagram and a honeycomb diagram for indications.present_solution
34
The slide uses a three-column layout to define technical constraints for drug development.present_solution
35
The table uses a color-coded heatmap to indicate performance against criteria.compare_peers
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.show_traction
37
The chart is a waterfall plot showing drug response scores across many patient samples, color-coded by diagnosis.show_traction
38
The slide uses a heatmap to correlate '617 sensitivity with synergy outcomes for three different drug combinations.present_solution
39
Venn diagram shows overlap of gene modulation; line charts show dose-response for POLR2A and HNRNPDL.analyze_data
40
The slide uses a 3D molecular visualization as a background element.show_traction
41
The slide showcases a successful asset development case study involving AI-driven design.present_solution
42
The slide uses a traffic-light color coding system to highlight the competitive advantage of the company's drug candidate.compare_peers
43
The slide uses a process-oriented layout to explain the company's methodology.present_solution
44
The background features a 3D molecular visualization, likely representing the LSD1 protein or the drug binding to it.plan_implementation
45
Uses MIDD (Model-informed drug development) as a core methodology.plan_implementation
46
The slide uses a human anatomy diagram to map specific disease indications to their respective patient counts.size_opportunity
47
Includes a biological pathway diagram showing LSD1 interactions with various complexes and substrates.present_solution
48
Includes a biological pathway diagram and supporting bullet points on therapeutic mechanism and safety profile.present_solution
49
The slide uses a process flow diagram to explain the therapeutic mechanism and competitive advantage of the '539 molecule.present_solution
51
The slide uses a three-column layout to define the technical requirements for the drug candidate.present_solution
52
The slide uses a traffic-light color coding system to indicate performance against criteria.compare_peers
53
The slide uses a linear process flow to explain a complex drug discovery pipeline.present_solution
54
The chart illustrates a Pareto front in drug discovery, highlighting that the 'best' molecules (on the front) are not always the most information-rich for furthpresent_solution
55
The slide uses two distinct chart types (dot plot and line chart with error bars) to demonstrate safety advantages.present_solution
56
Includes box plots for overall differentiation and line plots for patient-specific heterogeneity categorized by differentiation level.show_traction
57
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across 6 different drug combinations.show_traction
58
The slide shows two charts: a line chart for tumour volume over time and a dot plot for plasma pro-GRP concentration. Statistical significance markers are preseshow_traction
59
Includes a heatmap showing synergy scores across cell lines and two dose-response line charts showing increased inhibition in combination.present_solution
60
The heatmap displays AUC (Response) values across 16 patient samples for three different treatments.frame_problem
63
The slide uses a stylized molecular visualization as a background element.show_traction
65
Scientific diagram showing the BCR and TLR signaling pathways converging on MALT1 and NF-kB.present_solution
66
The slide uses a three-column layout to define the core pillars of the drug development strategy.present_solution
68
The slide uses a heatmap-style table to visualize performance against criteria, with a specific callout box around the UGT1A1 row.compare_peers
69
The slide outlines a multi-stage pipeline: Initiate, Analyse, Evolve, 2D Models, 3D Models, and Active Learning.present_solution
70
The slide highlights the technical methodology behind the 565 candidate development, specifically focusing on allosteric site constraints and permeability.present_solution
71
The slide demonstrates efficacy and synergy in vivo for a drug candidate ('565) in DLBCL models.show_traction
72
The slide uses two dose-response curves to demonstrate selectivity.present_solution
73
The table uses a heatmap-style color coding (red/green) to indicate risk levels for UGT1A1 inhibition parameters.compare_peers
74
The slide uses a two-column layout to contrast PK data with Toxicology/Safety data.present_solution